Navigation Links
US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022
Date:1/15/2014

TORONTO, Jan. 15, 2014 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States and European transcatheter embolization and occlusion (TEO) device markets will expand moderately through 2022, with embolization particles representing one of the fastest-growing segments. In particular, increasing interest in drug-eluting beads (DEBs) and radioembolization spheres in interventional oncology has fueled rapid growth of these markets.

The European radioembolization sphere market will be further boosted by expansion in the United Kingdom a result of the National Health Service's (NHS) Commissioning through Evaluation program, which will evaluate radioembolization as a treatment for liver cancer and fund its use in a small number of patients. While the NHS has yet to decide on widespread coverage of radioembolization, the program will improve awareness of the procedure and encourage other countries to consider expanding reimbursement.

In both the US and Europe, there is considerable competitive activity in the embolization particle market. A recent acquisition made by BTG in the radioembolization space and the US launch of a new DEB product, ONCOZENE, by CeloNova BioSciences have reshaped the competitive landscape. Competitive dynamics are also shifting in the peripheral vascular (PV) plug space. Although St. Jude Medical's AMPLATZER line has historically held a monopoly, in 2013, Reverse Medical's Micro Vascular Plug gained US and European approval, and EndoShape's Medusa Vascular gained approval in the US. ArtVentive Medical Group's EOS device, which is increasingly being used in Europe in the emerging pelvic congestion syndrome indication, will also likely enter the US market in the near future.

"While St. Jude Medical dominated the PV plug market in 2013, we'll start to see the impact of new entrants in 2014," said MRG Senior Analyst Sean Messenger. "These smaller, innovative PV plug companies represent attractive acquisition targets for PV coil companies that want to offer comprehensive product portfolios in the TEO space."

Millennium Research Group's US Markets for Transcatheter Embolization and Occlusion Devices 2014 and European Markets for Transcatheter Embolization and Occlusion Devices 2014 reports include unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for interventional neuroradiology (INR) embolization coils, INR coiling-assist devices, INR flow-diverting devices, PV embolization coils, PV plugs, embolization particles, liquid embolics and accessory devices in the United States, France, Germany, Italy, Spain and the United Kingdom. Supplemental country coverage is also available for Austria, Belgium, the Czech Republic, Denmark, Finland, Greece, Hungary, the Netherlands, Norway, Poland, Portugal, Romania, Sweden, Switzerland and Ukraine, as well as in aggregate for the rest of the European countries.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CorMedix Awarded European Patent for Neutrolin
2. The US and European Video and High-Tech Hardware Device Markets Will Reach a Combined Value of Over $4.6 Billion by 2022
3. Oramed Receives Patent in the European Union for the Oral Delivery of Insulin
4. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
5. RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
6. MGB Biopharma Adds its Support to European Antibiotic Awareness Day
7. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
8. European Home Healthcare Market Report 2013-2017: Products, Services & Telehealth
9. European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
10. HighPoint Solutions and InnoPeritus Partner to Provide Unprecedented Consultative Services in the European Life Sciences Market
11. US and European Regulators Accept for Review OMS302 Marketing Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):